arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Axsome Therapeutics, Inc.

AXSM
$129.90 ▼ -7.05 (-5.15%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
49 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

Axsome Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $6.8B
Dividend Yield —
Revenue Growth 51.9% ↗
Op. Margin -4.3% ↗
ROIC -5.0% ↗
FCF / Share $-0.18 ↗
Trailing P/E —
Price / Book 64.8x
FCF Yield —
Debt / Equity 1.12
info Valuation on last close. End-of-day price, Nov 5, 2026.

49-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$259.69M
↑ +51.9% —
Net Income Profit after all expenses
$-64.54M
↓ -8.6% —
Operating Margin Operating profit as % of sales
-4.3%
↑ +81.3% 9th
FCF / Share Free cash flow per share
$-0.18
↑ +71.4% —
Long-Term Debt Long-term obligations
$118.07M
— +0.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
9
Returns ↓
2
Financial Health →
25
Cash Quality ↓
41

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 13 years · 49 quarters